호르몬 대체요법과 안 질환: 제4기 국민건강영양조사자료 = Hormone Replacement Therapy and Eye Diseases: KNHANES 4

국문 초록 (Abstract)

목적: 호르몬대체요법과 안질환의 관계를 밝히고자 하였다. 대상과 방법: 5,808명의 제4기 국민건강영양조사를 완료한 여성중 호르몬 대체요법 시행 군과 받지 않은 군 간의 안질환 유병을 회귀분석을 통한 보정 평균을 비교하였다. 결과: 호르몬 대체요법을 시행 받은 군의 수는 480명(8.3%)이었고, 근시는 호르몬대체요법을 시행 군에서 44.5% (95%CI, 38.1-51.2), 시행 받지 않은 군에서 54.4% (95%CI, 52.6-56.1)이며, 원시는 시행 군에서 7.7% (95%CI, 5.5-10.6), 시행 받지 않은 군에서 4.5%(95%CI, 3.8-5.3)이며, 익상편은 시행 군에서 2.1% (95%CI, 1.3-3.3), 시행 받지 않은 군에서 3.3% (95%CI, 2.7-4.0)로 p-value 0.05 미만의 통계적 유의한 차이를 보였고, 당뇨망막증은 시행 군에서 5.6% (95%CI, 1.4-19.8), 시행 받지 않은 군에서 16.7% (95%CI, 13.0-21.2)로 p-value 0.053으로 통계적으로 의미 있는 경계에 놓여 있었다. 결론: 호르몬대체요법 시행 군에서 근시, 익상편과 당뇨망막증은 적었고, 원시는 많았다.

다국어 초록 (Multilingual Abstract)

Purpose: To identify the association between hormone replacement therapy and eye diseases. Methods: The fourth Korea National Health and Nutrition Examination Survey (KNHANES IV) is a nationwide survey. The study included 5,808 females who completed the KNHANES IV. The prevalence of eye disease of adjusted mean using linear regression analysis between the subjects who had hormone replacement therapy and those who did not have the therapy was analyzed. Results: Among the 5,808 females, 480 (8.3%) received hormone replacement therapy. The adjusted prevalence of myopia was 44.5% (95% CI, 38.1-51.2) in the subjects who received hormone replacement therapy, and 54.4% (95% CI, 52.6-56.1) in those who did not have the therapy. The adjusted prevalence of hyperopia was 7.7% (95% CI, 5.5-10.6) in subjects who received hormone replacement therapy and 4.5% (95% CI, 3.8-5.3) in those who did not have the therapy. The adjusted prevalence of pterygium was 2.1% (95% CI, 1.3-3.3) in the subjects who received hormone replacement therapy and 3.3% (95% CI, 2.7-4.0) in those who did not have the therapy. All the results were statistically significant with a p-value <0.05. The adjusted prevalence of diabetic retinopathy was 5.6% (95% CI, 1.4-19.8) in the subjects who received hormone replacement therapy and 16.7% (95% CI, 13.0-21.2) in those who did have the therapy. The p-value was 0.053, which is marginally statistically significant. Conclusions: The adjusted prevalence of myopia, pterygium, and diabetic retinopathy in the subjects who received hormone replacement therapy was low, although hyperopia was statistically significantly high. J Korean Ophthalmol Soc 2012;53(10):1445-1450